HomeNewsBusinessEconomyBIG STORY | What the fall in NRI remittances means for India

BIG STORY | What the fall in NRI remittances means for India

In this episode of Big Story, Moneycontrol's Sakshi Batra tells us why NRI remittances are falling and its implications for India

April 29, 2020 / 16:57 IST
Story continues below Advertisement

COVID-19 has hit India’s steady flow of remittances. With many major economies on the verge of a recession this year, Indians living in those countries are likely to send lesser money back home.

NRI remittances have also been India’s bulwark in financing its current account deficit. Thankfully, due to the record low oil prices, India's import bill is likely to be within the comfort zone, thus putting less pressure on the current account deficit.

Story continues below Advertisement

"In India, remittances are projected to fall by about 23 percent in 2020, to $64 billion – a striking contrast with the growth of 5.5 percent and receipts of $83 billion seen in 2019,” the World Bank said in a report on the impact of COVID-19 on migration and remittances released on April 22.

The UAE, the US, Saudi Arabia, Qatar, Kuwait, Oman, United  Kingdom and Malaysia account for about 80 percent of total remittances received by India. The UAE, with more than 3.3 million Indian expatriates, has traditionally been the largest source of remittances to India.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show